JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

A

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

A

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

A

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

A

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

A

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

Search

Insulet Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

182.77 -3.03

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

182.19

Max

190.57

Pagrindiniai rodikliai

By Trading Economics

Pajamos

14M

102M

Pardavimai

78M

784M

P/E

Sektoriaus vid.

57.721

60.328

Pelno marža

12.962

Darbuotojai

5,400

EBITDA

17M

177M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+70.81% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.9B

14B

Ankstesnė atidarymo kaina

185.8

Ankstesnė uždarymo kaina

182.77

Naujienos nuotaikos

By Acuity

54%

46%

302 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Insulet Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-27 23:15; UTC

Svarbiausios naujienos

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026-04-27 23:08; UTC

Uždarbis
Pagrindinės rinkos jėgos

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026-04-27 23:48; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026-04-27 23:42; UTC

Rinkos pokalbiai

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026-04-27 23:34; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026-04-27 23:30; UTC

Rinkos pokalbiai

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026-04-27 23:08; UTC

Rinkos pokalbiai

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026-04-27 22:42; UTC

Rinkos pokalbiai

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026-04-27 22:10; UTC

Uždarbis

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026-04-27 21:56; UTC

Uždarbis

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026-04-27 21:44; UTC

Uždarbis

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026-04-27 21:43; UTC

Uždarbis

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026-04-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-27 20:39; UTC

Uždarbis

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Akcijų palyginimas

Kainos pokytis

Insulet Corp Prognozė

Kainos tikslas

By TipRanks

70.81% į viršų

12 mėnesių prognozė

Vidutinis 323.79 USD  70.81%

Aukščiausias 435 USD

Žemiausias 220 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Insulet Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

16

Pirkti

3

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

252.29 / 259.38Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

302 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat